Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024, prior guidance of $290 to $300 million for full year 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TGTX Earnings this Week: How Will it Perform?
- TG Therapeutics initiated with a Buy at TD Cowen
- TG Therapeutics price target raised to $38 from $34 at B. Riley
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics presents updated data from ENHANCE Phase 3b trial of BRIUMVI